Alector, Inc. (ALEC): Business Model Canvas [Apr-2026 Updated]

You're looking at Alector, Inc., a clinical-stage biotech that just made a major strategic pivot after a tough Phase 3 result, so the old playbook is out. Honestly, the new Alector, Inc. story hinges entirely on its proprietary Alector Brain Carrier (ABC) drug delivery platform, which they are now pushing hard, even after a significant workforce reduction. To be fair, they still have a decent runway with $291.1 million in cash as of Q3 2025, but they are burning through it, guiding R&D spend between $130M to $140M for the year, while banking on only $13M to $18M in collaboration revenue from partners like GlaxoSmithKline. If you want to see how this high-stakes, immuno-neurology focused model is structured now-from key activities to the cost structure-dive into the full canvas below.

Alector, Inc. (ALEC) - Canvas Business Model: Key Partnerships

You're looking at the structure of Alector, Inc. (ALEC) as of late 2025, and the partnerships are definitely where the near-term value-and risk-is concentrated. The collaboration revenue stream is volatile, reflecting the stage-gate nature of these deals.

GlaxoSmithKline (GSK) for nivisnebart (AL101) co-development

The collaboration with GlaxoSmithKline (GSK) centers on the progranulin franchise, including nivisnebart (AL101/GSK4527226) for Alzheimer's disease (AD) and latozinemab (AL001) for frontotemporal dementia (FTD-GRN). Alector, Inc. initially received 700 million in upfront payments from this agreement. Furthermore, Alector, Inc. remains eligible to receive up to an additional 1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments.

For the Phase 2 PROGRESS-AD trial of nivisnebart in early AD, enrollment was completed in April 2025, with an independent interim analysis planned for the first half of 2026. Following the Phase 2 proof-of-concept, Alector, Inc. and GSK share global development responsibilities and all associated costs.

Financially, the revenue recognition from this partnership is lumpy. Collaboration revenue for the quarter ended September 30, 2025, was 3.3 million. Management's guidance for the full year ending 2025 anticipates total collaboration revenue to be between 13 million and 18 million. As of September 30, 2025, Alector, Inc.'s cash, cash equivalents, and investments totaled 291.1 million.

The profit and loss sharing structure for commercialization in the U.S. is an equal split. Outside the U.S., GSK holds exclusive commercialization rights for both AL001 and AL101, with Alector, Inc. eligible for tiered royalties.

Academic and clinical research institutions for trial execution

Alector, Inc. uses external institutions to execute its clinical programs. The PROGRESS-AD Phase 2 trial for AL101 is a global, randomized, double-blind, placebo-controlled study.

• The PROGRESS-AD trial is a 76-week study.
• The trial is investigating nivisnebart in individuals with early Alzheimer's disease.

Contract Research Organizations (CROs) for clinical operations

Clinical operations rely on Contract Research Organizations (CROs) for execution, but specific contract values or the names of the primary CRO partners for 2025 are not publicly detailed in the latest financial disclosures.

The Michael J. Fox Foundation (MJFF) for research grants

The Michael J. Fox Foundation (MJFF) is a significant funder in the Parkinson's space, supporting therapeutic development. In April and May 2025, MJFF announced 69 grants totaling 60.6 million. For their Therapeutics Pipeline Program, award amounts can range from 250,000 for smaller programs up to 2M for larger, multi-stage preclinical and/or clinical programs. The Aligning Science Across Parkinson's (ASAP) Collaborative Research Network can award up to 3M per year for three years.

The types of projects MJFF prioritizes for funding include those that aim to slow or stop Parkinson's progression by targeting mechanisms like neuroinflammation.

Alector, Inc. (ALEC) - Canvas Business Model: Key Activities

You're hiring before product-market fit, so the focus is entirely on advancing the pipeline through rigorous execution of R&D milestones. Here's the quick math on what Alector, Inc. spent and achieved in their core activities as of the third quarter of 2025.

Executing the Phase 2 PROGRESS-AD trial for nivisnebart (AL101)

The 76-week, global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial for nivisnebart (AL101/GSK4527226) in early Alzheimer's disease reached a key operational milestone.

• Enrollment completion occurred in April 2025.
• The trial is designed for 76-week dosing duration.
• An independent interim analysis is scheduled for the first half of 2026.

Preclinical development of Alector Brain Carrier (ABC) enabled assets

Alector, Inc. is advancing multiple assets leveraging the proprietary Alector Brain Carrier (ABC) platform to enhance brain delivery.

The company is progressing these candidates toward IND-enabling studies. Still, the recent discontinuation of the latozinemab INFRONT-3 Phase 3 trial in October 2025 shows the binary nature of this work.

Core research and discovery in immuno-neurology

The financial commitment to core research and discovery is reflected in the Research and Development (R&D) spend, which has seen a strategic reduction following workforce reductions of approximately 47%.

For the quarter ended September 30, 2025, total research and development expenses were $29.4 million, down from $48.0 million for the same period in 2024. This spending is managed against the full-year expectation.

As of September 30, 2025, Alector, Inc.'s cash, cash equivalents, and investments stood at $291.1 million, which management anticipates will fund operations through 2027.

Managing intellectual property and patent portfolio

Protecting the core technology, especially the ABC platform, is a key activity requiring ongoing legal and administrative resources.

As of October 31, 2025, the intellectual property landscape included:

• Total Documents Applications and Grants: 388.
• Granted Patents: 134.
• Pending Applications: 150.

The U.S. Patent and Trademark Office issued a patent covering methods of treatment using latozinemab in the third quarter of 2025.

Alector, Inc. (ALEC) - Canvas Business Model: Key Resources

You're looking at the core assets Alector, Inc. (ALEC) is relying on to push its next-generation therapies through the clinic, especially after the recent Phase 3 setback. The most critical resource here is the Proprietary Alector Brain Carrier (ABC) technology platform. This platform is designed to get therapeutics, like antibodies and enzymes, across the blood-brain barrier (BBB), which is the gatekeeper for most neurological drugs. The company is selectively applying this technology to its next-generation pipeline, betting big on its ability to enhance delivery, efficacy, and safety.

The ABC platform is the engine driving the near-term focus. Here's what that platform is currently enabling:

• Targeted delivery of therapeutics across the BBB.
• Development of AL137, an anti-amyloid beta antibody, with an IND target filing in 2026.
• Advancement of AL050, a GCase enzyme replacement therapy, with an IND submission anticipated in 2027.
• Progression of the ADP064-ABC anti-tau siRNA program.

Financially, Alector, Inc. is holding a solid position to fund this focused development. As of September 30, 2025, the company reported cash, cash equivalents, and investments of \$291.1 million. Honestly, management anticipates this cash position is sufficient to fund operations through 2027, which buys them critical time to hit the upcoming IND milestones. This runway extension was helped by raising approximately \$14.7 million in net proceeds via an at-the-market (ATM) equity offering in September 2025, plus another \$5.3 million in October 2025.

Here's a quick look at the financial foundation and the near-term pipeline targets that this cash must support:

The human capital is also a key resource, though it has recently been streamlined. Alector, Inc. possesses specialized scientific personnel with expertise spanning neurodegeneration and immunology, which is necessary to advance their genetically validated programs. To focus resources on the highest-priority programs, the company implemented a reduction in force of approximately 47% in October 2025. This move was defintely aimed at preserving that cash runway through 2027.

Intellectual property forms another vital layer. Alector, Inc.'s strategy centers on generating and validating unique antibody drugs targeting crucial pathways, supported by a growing patent portfolio. For instance, in the third quarter of 2025, the U.S. Patent and Trademark Office issued a patent specifically covering methods of treatment using latozinemab in individuals with FTD-GRN. The company's overall focus areas for development include Nervous System Diseases, with 10 programs noted, and Immune System Diseases, with 1 program noted in one recent analysis.

Alector, Inc. (ALEC) - Canvas Business Model: Value Propositions

You're looking at Alector, Inc. (ALEC) as of late 2025, and the value proposition is entirely centered on solving the seemingly intractable problem of neurodegeneration through a novel scientific lens. This isn't about incremental improvement; it's about fundamentally changing how we approach diseases like Alzheimer's and Parkinson's. The financial reality underscores this high-risk, high-reward proposition: the company reported a net loss of $34.7 million for the third quarter of 2025, yet they are spending heavily to pursue this vision, with 2025 R&D expenses guided between $130 million and $140 million.

The core value Alector, Inc. offers is its pioneering approach to immuno-neurology to target root causes of disease. They are not just managing symptoms; they are developing therapies designed to restore healthy immune function in the brain to counteract the underlying pathology of these conditions. This strategy aims to:

• Remove toxic proteins.
• Replace missing proteins.
• Restore immune and nerve cell function.

A major differentiator in delivering this value is the proprietary Alector Brain Carrier (ABC) platform, which develops brain-penetrant therapeutics. This technology is key because it allows for the delivery of large molecules across the blood-brain barrier (BBB) via peripheral dosing, which is a massive hurdle cleared for CNS drug development. The platform's versatility is being applied across several next-generation candidates:

This platform directly addresses the high unmet need in Alzheimer's and Parkinson's diseases. For Alzheimer's disease, the Phase 2 PROGRESS-AD trial for nivisnebart (AL101/GSK4527226) completed enrollment ahead of schedule in April 2025, with an independent interim analysis planned for the first half of 2026. This is a critical data point for the AD program. For frontotemporal dementia due to a GRN gene mutation (FTD-GRN), the pivotal Phase 3 INFRONT-3 trial for latozinemab concluded in October 2025 without demonstrating clinical benefit, leading to discontinuation. Still, the company's focus on genetically-validated targets remains a core value proposition.

The ultimate value proposition lies in the potential for first- or best-in-class therapies for neurodegeneration. The ABC technology is specifically designed to enhance drug delivery, achieve deeper brain penetration, and allow for efficacy at lower doses, which could ultimately improve patient outcomes while reducing costs. The company's current cash position of $291.1 million as of September 30, 2025, is projected to fund operations through 2027, giving them the necessary runway to generate the data that will prove this potential, despite the recent clinical setback and the current revenue stream being modest-Q3 2025 collaboration revenue was only $3.3 million.

Alector, Inc. (ALEC) - Canvas Business Model: Customer Relationships

You're looking at the relationships Alector, Inc. maintains with its key external stakeholders as of late 2025, which is heavily influenced by its late-stage clinical progress and recent strategic restructuring.

High-touch, strategic collaboration management with GSK

The relationship with GlaxoSmithKline (GSK), which began in July 2021 to develop progranulin-elevating monoclonal antibodies, has seen a major shift following trial outcomes. Alector, Inc. and GSK are discontinuing further studies of latozinemab (AL001) in frontotemporal dementia due to a progranulin gene mutation (FTD-GRN) after the Phase 3 INFRONT-3 trial did not meet its clinical co-primary endpoint of slowing disease progression. The trial did, however, show a statistically significant effect on the biomarker co-primary endpoint of plasma progranulin concentrations. This required close, joint management of the trial data analysis and the subsequent decision to discontinue the open-label extension and continuation study for latozinemab. The collaboration continues on AL101/GSK4527226 (nivisnebart) for Alzheimer's disease, which is in Phase 2 PROGRESS-AD.

Investor Relations (IR) for capital markets and shareholder updates

Investor communication centers on financial stability and pipeline advancement following a significant workforce reduction of approximately 47%. The primary message is that the current cash position is sufficient to fund operations through 2027. Updates are frequent, with Q3 2025 results released on November 6, 2025, detailing the financial impact of program discontinuation and cost-saving measures. The company raised approximately $20.0 million through at-the-market (ATM) equity offerings across September and October 2025.

Here are the key financial metrics reported as of September 30, 2025, which form the basis of shareholder updates:

Direct engagement with clinical trial investigators and sites

Engagement with investigators is focused on ongoing and recently completed trials. The Phase 2 PROGRESS-AD trial of AL101/GSK4527226 in early Alzheimer's disease reached its enrollment completion milestone in April 2025. Trial completion for PROGRESS-AD is expected in 2026, with an independent interim analysis planned for the first half of 2026. This requires continued, direct coordination with the global sites running the trial. Conversely, engagement related to the INFRONT-3 trial is shifting to data presentation and close-out activities following the October 2025 topline results announcement.

Key clinical milestones driving investigator interaction include:

• Enrollment completion for PROGRESS-AD in April 2025.
• Trial completion for PROGRESS-AD expected in 2026.
• Interim analysis for PROGRESS-AD planned for 1H 2026.
• Discontinuation of latozinemab studies following October 2025 results.

Scientific publications to build credibility with the research community

Building credibility relies on peer-reviewed validation of the Alector Brain Carrier (ABC) platform and its candidates. Alector, Inc. published a manuscript in July 2025 in Alzheimer's Research & Therapy. This publication detailed the preclinical and Phase 1 study results for AL101 (GSK4527226), showing consistent elevation of progranulin (PGRN) levels. The company is advancing several ABC-enabled leads toward Investigational New Drug (IND)-enabling studies, with IND targets set for 2026 (AL137) and 2027 (AL050).

Finance: draft 13-week cash view by Friday.

Alector, Inc. (ALEC) - Canvas Business Model: Channels

You're looking at how Alector, Inc. gets its value proposition-novel immuno-neurology therapies-to the world, which is heavily reliant on strategic partners and capital markets right now.

The primary channel for late-stage asset development is the global pharmaceutical partnership with GSK for progranulin-elevating monoclonal antibodies, specifically latozinemab and AL101/GSK4527226. This channel involves shared development costs and potential milestone payments, though the revenue recognized from this partnership has fluctuated significantly in 2025. For instance, collaboration revenue for the quarter ended September 30, 2025, was reported as $3.3 million, a notable decrease from the $15.3 million seen in the same period of 2024. To be fair, the Q2 2025 collaboration revenue was $7.9 million, and Q1 2025 saw $3.7 million. Management's guidance for the full year ending 2025 anticipates total collaboration revenue to fall between $13 million and $18 million. This partnership is crucial for advancing assets like latozinemab, which is in the pivotal INFRONT-3 Phase 3 trial, with topline data expected by mid-fourth quarter 2025.

Drug delivery and clinical validation rely on a network of clinical trial sites and research centers. The PROGRESS-AD Phase 2 trial, evaluating AL101 in early Alzheimer's disease, completed enrollment in April 2025. This global trial targeted 282 participants. The latozinemab INFRONT-3 Phase 3 trial enrolled participants across multiple sites in North America, Europe, Argentina, and the Asia-Pacific region. These sites are the physical channel through which Alector, Inc. gathers the necessary safety and efficacy data to move candidates toward potential regulatory submissions, like the planned Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions in 2026 for latozinemab, pending trial outcome.

For external stakeholders, Alector, Inc. uses direct communication via investor conferences and press releases to disseminate information. The company hosted its Q2 2025 Earnings Conference Call on August 7, 2025, at 4:30 p.m. ET. Key data updates are also channeled directly; for example, topline results from the Phase 3 INFRONT-3 trial were announced via press release on October 21, 2025. Furthermore, the company participated in several investment conferences, including the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025. This consistent cadence of updates keeps the investment community informed about clinical progress and financial health.

To support its operations, especially given the anticipated total research and development expenses between $130 million and $140 million for 2025, Alector, Inc. utilizes At-The-Market (ATM) equity offerings for capital raising. This is a direct channel to the public equity markets for non-dilutive funding outside of a traditional offering structure. The company actively tapped this in late 2025. Specifically, approximately $14.7 million in net proceeds were raised through the ATM offering in September 2025, followed by an additional raise of $5.3 million in October 2025. This recent capital infusion helps support the cash position, which stood at $291.1 million as of September 30, 2025, with management anticipating this will fund operations through 2027.

Here's a quick look at some of the key financial and operational metrics that define these channels as of late 2025:

The company communicates key milestones through various means, which you can track via their investor relations updates:

• Reported Q3 2025 Financial Results on November 6, 2025.
• Announced Topline Results from Latozinemab Phase 3 Trial on October 21, 2025.
• Hosted Q2 2025 Earnings Conference Call on August 7, 2025.
• Reported Q2 2025 Financial Results on August 7, 2025.
• Reported Q1 2025 Financial Results on May 8, 2025.

The partnership channel is also defined by the clinical programs it supports, which are the core of Alector, Inc.'s value proposition:

• Latozinemab (AL001) in pivotal Phase 3 INFRONT-3 trial for FTD-GRN.
• AL101/GSK4527226 in Phase 2 PROGRESS-AD trial for early Alzheimer's disease.
• Both programs are part of the collaboration with GlaxoSmithKline plc.

Alector, Inc. (ALEC) - Canvas Business Model: Customer Segments

You're looking at Alector, Inc. (ALEC) at a critical juncture, post-latozinemab data readout. The customer segments are now heavily weighted toward those interested in the remaining pipeline, specifically the AL101/GSK4527226 program and the preclinical assets. The focus has sharpened considerably after the October 2025 topline results from the INFRONT-3 Phase 3 trial.

Major pharmaceutical companies seeking neurodegenerative pipeline assets

The primary pharmaceutical partner segment is defined by large companies looking to acquire or co-develop assets leveraging Alector, Inc.'s proprietary Alector Brain Carrier (ABC) technology. The relationship with GlaxoSmithKline (GSK) is the most concrete example here, covering both the now-discontinued latozinemab and the ongoing nivisnebart (AL101/GSK4527226) program for early Alzheimer's disease (AD). This segment provides non-dilutive funding, though it is volatile; for the full year 2025, Alector, Inc. guides collaboration revenue between $13 million and $18 million.

The financial reality of this segment is clear from the recent revenue figures:

Still, the failure of latozinemab means Alector, Inc. is now concentrating resources on its only remaining clinical candidate, nivisnebart (AL101/GSK4527226).

Patients with genetically-validated neurodegenerative diseases

This segment is highly specific, focusing on patients with defined genetic drivers of their condition, which allows for more targeted trial design. The most significant patient group targeted recently was for Frontotemporal Dementia with a granulin gene mutation (FTD-GRN), which was the focus of the latozinemab trial. The INFRONT-3 trial included 103 symptomatic and 16 at-risk FTD-GRN patients.

The current focus shifts to patients with early AD, the target population for nivisnebart (AL101/GSK4527226) in the PROGRESS-AD study. The trial completed enrollment in April 2025.

• Patients with FTD due to a GRN mutation (latozinemab target).
• Patients with early Alzheimer's disease (nivisnebart target).
• Patients with Parkinson's disease (preclinical GCase ERT target).

Specialist clinicians and neurologists running clinical trials

These are the key opinion leaders and investigators who execute the trials, providing the necessary infrastructure and patient access. They are crucial for advancing the pipeline toward potential regulatory filings. The PROGRESS-AD Phase 2 trial is a major focus for this group right now, having completed enrollment in April 2025.

The next milestone for clinicians involved in the AL101 program is the independent interim analysis, planned for the first half of 2026.

• Investigators in the PROGRESS-AD Phase 2 trial for early AD.
• Investigators who participated in the pivotal 96-week INFRONT-3 Phase 3 trial.
• Specialists involved in preclinical IND-enabling studies for AL137 (anti-Aβ) and AL050 (GCase ERT).

Institutional and retail investors funding the R&D pipeline

This segment provides the capital necessary to fund the high Research and Development (R&D) expenses, which for the full year 2025 are guided between $130 million and $140 million. The investment thesis for this group hinges on the success of the remaining pipeline, particularly the ABC platform, given the cash runway extends into 2027 based on the $291.1 million cash position as of September 30, 2025.

The market's current valuation reflects the recent clinical setback:

The company also raised capital via an at-the-market (ATM) equity offering in September 2025, bringing in approximately $14.7 million in net proceeds, showing reliance on equity markets to supplement operational cash flow.

Alector, Inc. (ALEC) - Canvas Business Model: Cost Structure

The Cost Structure for Alector, Inc. (ALEC) is heavily weighted toward the discovery, development, and clinical execution of its novel therapeutic candidates, which is typical for a clinical-stage biotechnology firm.

Dominant Research & Development (R&D) expenses for the full year 2025 are guided to be between $130M to $140M. This R&D spend is the primary cost driver, encompassing all preclinical work, clinical trial execution, and drug supply manufacturing.

General & Administrative (G&A) costs for the full year 2025 are guided to fall between $55M to $65M. This covers essential corporate functions, executive leadership, and general operational overhead.

The October 2025 workforce reduction was a significant cost-alignment action following the Phase 3 INFRONT-3 trial results. This restructuring was intended to focus resources on the highest-priority programs, including the Alector Brain Carrier (ABC) platform candidates.

Here's the quick math on the restructuring: Total incremental restructuring charges associated with the October 2025 reduction in force are expected to be approximately $7.7 million. This reduction impacted approximately 75 employees. For context, Alector, Inc. had 238 full-time employees at the end of 2024, suggesting the 49% cut affected around 116 people based on that prior headcount.

Costs associated with clinical trial execution and manufacturing for drug supply are embedded within the R&D budget. For instance, R&D expenses for the third quarter ended September 30, 2025, were $29.4 million, a decrease from $48.0 million in the same period of 2024, partly due to reduced expenses for the AL002 and latozinemab programs following the Phase 3 outcome.

You can see the breakdown of recent operating costs below:

The nature of these costs is primarily focused on advancing the pipeline, which includes:

• Funding the pivotal INFRONT-3 Phase 3 trial for latozinemab (AL001) in frontotemporal dementia due to a GRN mutation.
• Supporting the ongoing Phase 2 PROGRESS-AD clinical trial of nivisnebart (AL101) in early Alzheimer's disease, in collaboration with GSK.
• Advancing the Alector Brain Carrier (ABC) enabled programs, such as AL137 (anti-amyloid beta antibody) and AL050 (GCase enzyme replacement therapy), toward IND-enabling studies.
• Personnel-related costs, which saw a reduction following the October 2025 reductions in force.

To be fair, the company is actively managing this burn rate, as evidenced by the Q3 2025 R&D expense of $29.4 million being lower than the $48.0 million reported in Q3 2024. Finance: draft 13-week cash view by Friday.

Alector, Inc. (ALEC) - Canvas Business Model: Revenue Streams

The revenue streams for Alector, Inc. as of late 2025 are almost entirely dependent on its strategic collaborations, given its status as a clinical-stage biotechnology company.

Collaboration revenue from partners like GSK is the primary recognized income source. Management continues to anticipate collaboration revenue to be between $13 million and $18 million for the full year 2025. This revenue recognition is inherently lumpy, tied to the satisfaction of performance obligations under the agreements, rather than steady sales. For instance, collaboration revenue for the third quarter ended September 30, 2025, was reported at $3.3 million, a significant decrease from the $15.3 million recognized in the same period of 2024. This drop was mainly due to the satisfaction of obligations associated with the AL002 program and the latozinemab FTD-C9orf72 Phase 2 trial. The nine-month total for 2025 reached $14.83 million, putting the company squarely within its guided range.

The volatility of this revenue model is clearly illustrated by the quarterly progression in fiscal year 2025:

Milestone payments tied to clinical and regulatory progress represent significant potential, though not guaranteed, future revenue. Under the strategic global collaboration with GlaxoSmithKline plc (GSK) for latozinemab (AL001) and AL101, Alector, Inc. is eligible to receive up to an additional $1.5 billion in clinical development, regulatory, and commercial launch-related milestone payments. The readout from the pivotal INFRONT-3 Phase 3 trial of latozinemab was expected by mid-fourth quarter 2025.

Reimbursement of R&D costs under collaboration agreements forms another component of the financial structure. The terms of the GSK Agreement dictate cost-sharing for late-stage studies of AL001 and AL101, where development costs are divided, with GSK covering 60% and Alector covering 40%. An exception exists where Alector is responsible for funding GSK\'s and its own development costs up to $140.5 million for the conduct of the initial Phase 2 clinical trial of AL101 in Alzheimer\'s disease. Revenue for research and development services is recognized as program costs are incurred, measured against the overall total expected costs to satisfy the performance obligation.

Minimal to no product sales are generated, as Alector, Inc. remains a clinical-stage company. Product sales for the third quarter of 2025 were $0.00. The company\'s focus is entirely on advancing its pipeline, which includes:

• AL137 for Alzheimer\'s disease, targeting IND filing in 2026.
• AL050 for Parkinson\'s disease, with an IND submission anticipated in 2027.
• ABC-enabled siRNA programs targeting tau and alpha-synuclein.

Finance: draft 13-week cash view by Friday.